Related Experiment Videos
Mannan-binding lectin: clinical significance and applications.
1Scottish National Blood Transfusion Service, National Science Laboratory, Ellen's Glen Road, EH17 7QT, Scotland, Edinburgh, UK.
Biochimica Et Biophysica Acta
|September 12, 2002
Summary
Mannan-binding lectin (MBL) is a key innate immunity protein. Low MBL levels increase infection risk, but MBL replacement therapy shows promise for treating related disorders.
Area of Science:
- Immunology
- Genetics
- Biochemistry
Background:
- Mannan-binding lectin (MBL) is a liver-synthesized protein crucial for innate immunity.
- Its concentration varies significantly due to genetic factors, impacting microbial recognition and complement activation.
- MBL insufficiency, affecting about 10% of the population, is linked to increased disease vulnerability.
Purpose of the Study:
- To review the evidence for MBL's role in innate immunity and disease susceptibility.
- To discuss the implications of MBL concentration variations.
- To evaluate preliminary findings of MBL replacement therapy.
Main Methods:
- Review of existing scientific literature on MBL genetics, function, and clinical associations.
- Analysis of data regarding MBL concentration variations and their impact on health.
- Assessment of preliminary MBL replacement therapy outcomes.
Main Results:
- Genetic variations in MBL significantly influence its plasma concentration, leading to a 1000-fold range in humans.
- Individuals with the lowest MBL levels are considered MBL insufficient and are more susceptible to infections.
- Early MBL replacement therapy results are encouraging, suggesting potential therapeutic benefits.
Conclusions:
- MBL plays a vital role in innate immunity, influencing susceptibility and disease course.
- Genetic determination of MBL levels has significant health implications.
- Further large-scale clinical trials are warranted to confirm the efficacy of MBL replacement therapy.